register

News & Trends - Pharmaceuticals

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for a person who is vulnerable to mental illness. 

1 million Australians suffer from depression in any one year.

New modelling by the University of Sydney’s Brain and Mind Centre confirms our fears, that the COVID-19 pandemic may see more deaths by suicide than by the virus itself. Predictions estimate a 25% increase to suicide rates and even higher rates for younger Australians.

In a recent submission to the Australian Department of Health, myDNA outlined how precision prescribing and pharmacogenomics could be a a new, and vitally important, dimension in the fight against such a shocking tidal wave of suicide and depression.

Specialists or GPs employ a level of guess work when recommending which anti-depressant treatment will work the first time. Studies show, 50% of the time, it will take three or more attempts of prescribing yet another medicine before the right treatment finally settles for that patient. This is because, when it comes to mental health, our genes run interference with how we react to medication.

Australian-based company, myDNA, has researched and developed a new way of determining the best antidepressant treatment for patients suffering from mental health disorders. This is achieved through a genetic test that can reveal a person’s ability to processes and metabolise certain medications. Known as Pharmacogenomics, this test is converted into vital knowledge for a doctor, who can then be certain that the medication they prescribe is personalised and accurate – the first time.

This type of test is now used by Australia’s leading pathology services providing such tests for doctors and support services in pharmacies across the country. 

Amid fears that this pandemic could spawn a ‘generational mental health crisis,’ pharmacogenomics and with it, precision prescribing, have an important role to play in protecting those Australians struggling with mental illness. 


ESG

Government joins forces with US and UK to decarbonise supply chains in pharmaceuticals and medical technologies

Government joins forces with US and UK to decarbonise supply chains in pharmaceuticals and medical technologies

Health Industry Hub | April 26, 2024 |

ESG: The Albanese Government signed a public statement of collaboration with the United States and United Kingdom to decarbonise healthcare […]

More


News & Trends - MedTech & Diagnostics

Bariatric surgery trumps Novo Nordisk’s Wegovy in cost-effectiveness and durability

Bariatric surgery trumps Novo Nordisk’s Wegovy in cost-effectiveness and durability

Health Industry Hub | April 26, 2024 |

MedTech & Diagnostics News: Bariatric surgery emerges as cost-effective, boasting superior and enduring weight loss outcomes over a five-year span […]

More


News & Trends - Pharmaceuticals

Aussie digital health company hits new milestone in AstraZeneca partnership

Aussie digital health company hits new milestone in AstraZeneca partnership

Health Industry Hub | April 26, 2024 |

Pharma News: Fewer than 50% of asthma patients adhere to their prescribed preventative medications. An Australian digital health company has […]

More


Digital & Innovation

Medical drone to reduce health equity gaps in rural and remote Australia

Medical drone to reduce health equity gaps in rural and remote Australia

Health Industry Hub | April 24, 2024 |

A specialised medical drone which increases accessibility to essential health services such as pathology, medicines, and telehealth services in rural […]

More


This content is copyright protected. Please subscribe to gain access.